- Home
- KXIN vs BLRX Comparison
KXIN vs BLRX Comparison
Compare KXIN & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KXIN
- BLRX
- Stock Information
- Founded
- KXIN 2015
- BLRX 2003
- Country
- KXIN China
- BLRX Israel
- Employees
- KXIN N/A
- BLRX N/A
- Industry
- KXIN Retail-Auto Dealers and Gas Stations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- KXIN Consumer Discretionary
- BLRX Health Care
- Exchange
- KXIN Nasdaq
- BLRX Nasdaq
- Market Cap
- KXIN 13.0M
- BLRX 10.8M
- IPO Year
- KXIN N/A
- BLRX 2011
- Fundamental
- Price
- KXIN $0.92
- BLRX $3.44
- Analyst Decision
- KXIN
- BLRX Buy
- Analyst Count
- KXIN 0
- BLRX 2
- Target Price
- KXIN N/A
- BLRX $26.00
- AVG Volume (30 Days)
- KXIN 88.8K
- BLRX 25.6K
- Earning Date
- KXIN 01-01-0001
- BLRX 05-27-2025
- Dividend Yield
- KXIN N/A
- BLRX N/A
- EPS Growth
- KXIN N/A
- BLRX N/A
- EPS
- KXIN N/A
- BLRX N/A
- Revenue
- KXIN N/A
- BLRX $28,940,000.00
- Revenue This Year
- KXIN N/A
- BLRX N/A
- Revenue Next Year
- KXIN N/A
- BLRX N/A
- P/E Ratio
- KXIN N/A
- BLRX N/A
- Revenue Growth
- KXIN N/A
- BLRX 502.92
- 52 Week Low
- KXIN $0.64
- BLRX $2.30
- 52 Week High
- KXIN $29.52
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- KXIN 44.49
- BLRX 62.14
- Support Level
- KXIN $0.86
- BLRX $2.30
- Resistance Level
- KXIN $0.94
- BLRX $3.09
- Average True Range (ATR)
- KXIN 0.09
- BLRX 0.18
- MACD
- KXIN -0.00
- BLRX 0.10
- Stochastic Oscillator
- KXIN 16.21
- BLRX 93.33
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.